Neuroscience imaging company IXICO plc (AIM: IXI) announced on Wednesday that it has further validated its AI-driven analysis platform, IXIQ.Ai, through collaboration with the Huntington's Disease Imaging Harmonisation (HD-IH) consortium. The breakthrough reinforces IXICO's position in neuroimaging and expands commercial opportunities in clinical trials.

HD-IH has completed the largest-ever Huntington's disease (HD) MRI dataset analysis, processing over 6,000 scans. Using this data, IXICO refined HD-Integrated Staging System (HD-ISS) cut-off values for key brain regions, aiding diagnosis, disease progression tracking and treatment decisions.

IXIQ.Ai's deep learning algorithm delivered high-quality volumetric measurements, offering deeper insights into HD progression and supporting its use as a potential surrogate endpoint in clinical trials.

The validation strengthens imaging biomarkers for biopharma partners, enhancing trial efficiency and drug development in neurodegenerative diseases. IXICO's collaboration with key industry players, including CHDI Foundation, uniQure, PTC Therapeutics, Asklepios BioPharmaceutical and Wave Life Sciences, continues to drive AI-powered advancements in neurological research.